Allergan’s Net Revenues Increase 2.9 percent in Q2-2018; Restasis Sales Decline

July 27, 2018: By Joan McKenna

Allergan’s total net revenues for the second quarter were $4.12 billion, a 2.9 percent increase year over year, the company announced July 26.

Allergan reported total eye care revenues of $587 million (-2.2 percent) in the US and $353.7 (+9.8 percent) internationally in Q2-2018, for a global total of $940.7 million.

Restasis’ net sales in the US were $318.2 million, a decrease of 5.4 percent from $336.4 million in Q2-2017. The dry eye drug’s international net sales in Q2-2018 totaled $16 million, for a global total of $334.2 million.

US net sales of retinal drug Ozurdex totaled $27.6 million, a 10.8 percent increase from $24.9 million in Q2-2017. Net sales internationally were $67.9 million, for a global total of $95.5 million.

Alphagan/Combigan net revenues in the US were $98.1 million in Q2-2018, compared with $96.4 million in Q2-2017.

The Dublin-headquartered company raised its full year guidance to $15.48 billion to $15.63 billion from $15.15 billion to $15.35 billion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT